Use of a predictive model derived from in vivo endophenotype measurements to demonstrate associations with a complex locus, CYP2A6.

This study demonstrates a novel approach to test associations between highly heterogeneous genetic loci and complex phenotypes. Previous investigations of the relationship between Cytochrome P450 2A6 (CYP2A6) genotype and smoking phenotypes made comparisons by dividing subjects into broad categories based on assumptions that simplify the range of function of different CYP2A6 alleles, their numerous possible diplotype combinations and non-additive allele effects. A predictive model that translates CYP2A6 diplotype into a single continuous variable was previously derived from an in vivo metabolism experiment in 189 European Americans. Here, we apply this model to assess associations between genotype, inferred nicotine metabolism and smoking behaviors in larger samples without direct nicotine metabolism measurements. CYP2A6 genotype is not associated with nicotine dependence, as defined by the Fagerström Test of Nicotine Dependence, demonstrating that cigarettes smoked per day (CPD) and nicotine dependence have distinct genetic correlates. The predicted metric is significantly associated with CPD among African Americans and European American dependent smokers. Individual slow metabolizing genotypes are associated with lower CPD, but the predicted metric is the best predictor of CPD. Furthermore, optimizing the predictive model by including additional CYP2A6 alleles improves the fit of the model in an independent data set and provides a novel method of predicting the functional impact of alleles without direct metabolism measurements. Lastly, comprehensive genotyping and in vivo metabolism data are used to demonstrate that genome-wide significant associations between CPD and single nucleotide polymorphisms are the result of synthetic associations.

[1]  L. Bierut,et al.  The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European–Americans , 2011, Pharmacogenetics and genomics.

[2]  S. David,et al.  Associations of CYP2A6 genotype with smoking behaviors in southern China. , 2011, Addiction.

[3]  David B. Goldstein,et al.  The Importance of Synthetic Associations Will Only Be Resolved Empirically , 2011, PLoS biology.

[4]  C. Gieger,et al.  Sequence variants at CHRNB3–CHRNA6 and CYP2A6 affect smoking behavior , 2010, Nature Genetics.

[5]  Ming D. Li,et al.  Genome-wide meta-analyses identify multiple loci associated with smoking behavior , 2010, Nature Genetics.

[6]  R. Tyndale,et al.  Hepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors , 2010, European Journal of Clinical Pharmacology.

[7]  B. Cohen,et al.  Epistasis in a quantitative trait captured by a molecular model of transcription factor interactions. , 2010, Theoretical population biology.

[8]  David B. Goldstein,et al.  Rare Variants Create Synthetic Genome-Wide Associations , 2010, PLoS biology.

[9]  Scott F. Saccone,et al.  The CHRNA5-CHRNA3-CHRNB4 nicotinic receptor subunit gene cluster affects risk for nicotine dependence in African-Americans and in European-Americans. , 2009, Cancer research.

[10]  John P. Rice,et al.  Multiple distinct risk loci for nicotine dependence identified by dense coverage of the complete family of nicotinic receptor subunit (CHRN) genes , 2009, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[11]  R. Tyndale,et al.  Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent , 2008, Human mutation.

[12]  R. Tyndale,et al.  A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent , 2008, Pharmacogenetics and genomics.

[13]  Leena Peltonen,et al.  Genetic linkage to chromosome 22q12 for a heavy-smoking quantitative trait in two independent samples. , 2007, American journal of human genetics.

[14]  H. McLeod,et al.  A Novel Duplication Type of CYP2A6 Gene in African-American Population , 2007, Drug Metabolism and Disposition.

[15]  C. Lerman,et al.  New lower nicotine cigarettes can produce compensatory smoking and increased carbon monoxide exposure. , 2007, Drug and alcohol dependence.

[16]  R. Tyndale,et al.  The Role of CYP2A6 in the Emergence of Nicotine Dependence in Adolescents , 2007, Pediatrics.

[17]  G. Swan,et al.  Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics , 2006, European Journal of Clinical Pharmacology.

[18]  C. Jepson,et al.  Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy , 2006, Molecular Psychiatry.

[19]  M. Haberl,et al.  Three haplotypes associated with CYP2A6 phenotypes in Caucasians , 2005, Pharmacogenetics and genomics.

[20]  H. McLeod,et al.  A novel CYP2A6*20 allele found in African-American population produces a truncated protein lacking enzymatic activity. , 2005, Biochemical pharmacology.

[21]  Neal L. Benowitz,et al.  Metabolism and Disposition Kinetics of Nicotine , 2005, Pharmacological Reviews.

[22]  R. Tyndale,et al.  Implications of CYP2A6 Genetic Variation for Smoking Behaviors and Nicotine Dependence , 2005, Clinical pharmacology and therapeutics.

[23]  M. Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[24]  R. Tyndale,et al.  Genetically decreased CYP2A6 and the risk of tobacco dependence: a prospective study of novice smokers , 2004, Tobacco Control.

[25]  R. Tyndale,et al.  Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. , 2004, Pharmacogenetics.

[26]  D. Hatsukami,et al.  Evaluation of carcinogen exposure in people who used "reduced exposure" tobacco products. , 2004, Journal of the National Cancer Institute.

[27]  M. Ingelman-Sundberg,et al.  Polymorphic NF-Y dependent regulation of human nicotine C-oxidase (CYP2A6). , 2004, Pharmacogenetics.

[28]  C. Pomerleau,et al.  Nicotine metabolite ratio as a predictor of cigarette consumption. , 2003, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[29]  S. Tokudome,et al.  Effects of polymorphism in Promoter Region of Human CYP2A6 Gene (CYP2A6*9) on Expression Level of Messenger Ribonucleic Acid and Enzymatic Activity In Vivo and In Vitro , 2003, Clinical pharmacology and therapeutics.

[30]  M. Ingelman-Sundberg,et al.  Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity , 2002, Human mutation.

[31]  R. Tyndale,et al.  Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[32]  P Bork,et al.  Integration of genome data and protein structures: prediction of protein folds, protein interactions and "molecular phenotypes" of single nucleotide polymorphisms. , 2001, Current opinion in structural biology.

[33]  R. Tyndale,et al.  Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. , 2000, Molecular pharmacology.

[34]  M. Jarvik,et al.  Nicotine Blood Levels and Subjective Craving for Cigarettes , 2000, Pharmacology Biochemistry and Behavior.

[35]  T. Moon The expectation-maximization algorithm , 1996, IEEE Signal Process. Mag..

[36]  A. C. Collins,et al.  Why some people smoke and others do not: new perspectives. , 1993, Journal of consulting and clinical psychology.

[37]  F. Gonzalez,et al.  The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. , 1990, Biochemistry.

[38]  S. Henikoff,et al.  Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm , 2009, Nature Protocols.

[39]  Nicholas G Martin,et al.  Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. , 2007, Human molecular genetics.

[40]  Scott F. Saccone,et al.  Novel genes identified in a high-density genome wide association study for nicotine dependence. , 2007, Human molecular genetics.

[41]  M. Schaar The Expectation-Maximization Algorithm , 2007 .